Elixir Medical placed its first DESolve drug-eluting stent in a patient in Germany since gaining its CE mark last year.
San Diego-based Arcturus Therapeutics added some juice to the RNAi buzz this week at the J.P. Morgan Healthcare Conference with results from a preclinical study that showed a hefty knockdown of the genetic disease transthyretin-mediated amyloidosis.
A nanoparticle with a specific code mechanism for release could allow drug-carrying vehicles to issue their payload upon contact with a specific biomarker. Now, researchers have developed a nanoparticle that uses coded DNA as this kind of "on-off" switch.
Canada-based Cynapsus has come up with the first sublingual option for the delivery of apomorphine to patients with Parkinson's disease to control their debilitating "off" episodes. This week, the company heralded results from a study comparing the thin film strip with a subcutaneous injection of the same drug, noting a reduction in side effects.
Crossing the blood-brain barrier is notoriously difficult, but overcoming that obstacle can have vast implications for the treatment of Alzheimer's, Huntington's and brain cancer. Now researchers at Roche have developed an antibody-based technique to "shuttle" large molecules into the brain, increasing exposure to the drug.
Analysts predict the global market for nanotechnology in medicine, which amounted to almost $79 billion in 2012, will surpass $177 billion by 2019.
India's health ministry is amending its rule for drug delivery systems to require any change in delivery method to undergo the full regulatory process of a new drug.
Like any moving target, cancer that has metastasized is notoriously difficult to treat. One of the major hurdles in cancer research is the detection of cancer cells that have spread in the body, but researchers at Cornell have developed a compound that could piggyback on white blood cells and deliver cancer-killing drugs very effectively.
To be able to make vaccines on site simply and effectively would greatly benefit remote areas that are often hampered by both distance from the source of vaccines and the difficulty of refrigeration. And researchers at the University of Washington have developed a nanotech delivery solution that could give vaccinators a leg up in the field.
Impax Laboratories is tapping Durect Corporation for its mid-stage transdermal patch Eladur, which is designed to ease the pain associated with shingles. For exclusive rights to the delivery tech, Impax agreed to pay up to $63 million to Durect when all is said and done.
Two birds with one stone? How about two drug targets with one delivery vehicle? Researchers in North Carolina have developed a single nanoparticle capable of carrying two separate drugs to two different locations in a cancer cell. The aim is to program the delivery in such a way that maximizes the efficiency of each drug.
In what could become a vast improvement to the delivery of gene therapy within the body, U.S. researchers have developed injectable DNA-carrying viruses that could eventually stop tumor growth or make chemotherapy more effective.
Cardio3 BioSciences pulled in €4 million ($5.5 million) in regional government funding to help support U.S. commercialization of its C-Cathez catheter for delivering stem cell treatments directly into the heart.
Inspired by natural biological "motors" made of protein, researchers at Purdue University have developed a DNA-based molecule that can "walk" across the surface of nanotubes, potentially carrying nanomeds with them for the purpose of drug delivery.
Biomedical engineers have developed a method to mass-produce artificial cells with dynamic membrane structures to be used in the research of new delivery techniques.
Back in 2006, Andrew Fire and Craig Mello won the Nobel Prize in Physiology or Medicine for their discovery of RNA interference in "silencing" genes. Today, nearly a decade later, the technology is still in limbo due to difficulties delivering the genetic material to cells.
Alnylam Pharmaceuticals began a Phase II study of its RNAi drug designed to treat TTR-mediated amyloidosis, an inherited, fatal disease caused by genetic mutations.
To get microscopic drug carriers swimming toward a target, German researchers took a cue from some of the best swimmers in nature: sperm cells.
Ovarian cancer cells are known to form resistance over time to chemotherapy, limiting the effect that standard cancer drugs can have on the disease. And now, researchers at Rutgers University have developed an RNA method to attack rampant proteins causing the drug resistance, allowing chemotherapy to then take out the cells.
Sanofi's Genzyme snagged a 6-month priority review from the FDA for what could become the first oral treatment for Gaucher disease, a rare genetic disorder that causes abnormal fat buildup in cells, enlarging organs in the body.